News articles about Windtree Therapeutics (NASDAQ:WINT) have been trending somewhat positive on Sunday, Accern reports. Accern ranks the sentiment of press coverage by monitoring more than twenty million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Windtree Therapeutics earned a daily sentiment score of 0.14 on Accern’s scale. Accern also gave media stories about the biotechnology company an impact score of 44.7468977069153 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the near future.
Shares of Windtree Therapeutics (NASDAQ:WINT) traded up 0.0000% on Friday, reaching $0.1995. The company’s stock had a trading volume of 29,969 shares. Windtree Therapeutics has a 52-week low of $0.18 and a 52-week high of $3.50. The firm has a 50 day moving average of $0.21 and a 200 day moving average of $0.76. The company’s market cap is $2.79 million.
Windtree Therapeutics (NASDAQ:WINT) last posted its earnings results on Monday, August 21st. The biotechnology company reported ($0.76) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.99) by $0.23. The company had revenue of $1.15 million for the quarter, compared to the consensus estimate of $0.40 million. Analysts predict that Windtree Therapeutics will post ($2.46) earnings per share for the current year.
A number of equities research analysts recently commented on WINT shares. Zacks Investment Research upgraded Windtree Therapeutics from a “hold” rating to a “buy” rating and set a $0.25 price target on the stock in a research report on Wednesday, August 30th. Stifel Nicolaus lowered Windtree Therapeutics from a “buy” rating to a “hold” rating in a research report on Friday, June 30th.
COPYRIGHT VIOLATION WARNING: “Somewhat Positive Press Coverage Somewhat Unlikely to Impact Windtree Therapeutics (WINT) Stock Price” was published by The Ledger Gazette and is the property of of The Ledger Gazette. If you are reading this piece on another site, it was illegally stolen and republished in violation of U.S. and international trademark & copyright laws. The legal version of this piece can be viewed at https://ledgergazette.com/2017/10/08/somewhat-positive-press-coverage-somewhat-unlikely-to-impact-windtree-therapeutics-wint-stock-price.html.
Windtree Therapeutics Company Profile
Windtree Therapeutics, Inc, formerly Discovery Laboratories, Inc, is a biotechnology company. The Company is focused on developing KL4 surfactant therapies for respiratory diseases and other potential applications. The Company operates through the research and development of products focused on surfactant therapies for respiratory disorders and diseases, and the manufacture and commercial sales of approved products segment.